← Leaderboards
Pamela E Knapp
University Of Kentucky
$12,958,922
Attributed
$19,057,744
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,057,744 · 9
By mechanism
R01$18,231,526 · 7
R21$826,218 · 2
Top collaborators
- Kurt Francis Hauser21 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Kurt Francis Hauser$27,368,955
- William F Maragos$2,562,799
- Charles F. Mactutus$6,378,382
- Audra L Stinchcomb$9,682,621
Others in their field
Top investigators on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Dennis R. Burton · Scripps Research Institute$265,781,207
- Myron S Cohen · Family Health International$253,611,624
- Wafaa M. El-Sadr · Columbia University Health Sciences$253,611,624
- George R Seage · Abt Associates, Inc.$221,990,872
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$151,998,810
Research focus
Exposure ToCellsIn VitroIn VivoInfectionNeuronsHiv-1MorphineAffectOpioid AbuseNeurogliaBrainOpioid ReceptorSignal TransductionAstrocytesMicrogliaHiv InfectionsCorpus Striatum StructureHiv Envelope Protein Gp120ChronicTransgenic MiceInflammationProteinsOligodendroglia
Grant awards (44)
pTau-related neuron and cognitive dysfunction in opioid-HIV comorbidity: Longitudinal and functional studies$697,583
R01 · FY2025 · DA · contact PI
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2025 · DA
pTau-related neuron and cognitive dysfunction in opioid-HIV comorbidity: Longitudinal and functional studies$697,583
R01 · FY2024 · DA · contact PI
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2024 · DA
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2023 · DA
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2023 · DA · contact PI
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity$678,736
R01 · FY2022 · DA
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2022 · DA · contact PI
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2021 · DA · contact PI
HIV opiate interactions in white matter pathology$514,511
R01 · FY2021 · DA
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,666
R01 · FY2020 · DA · contact PI
HIV opiate interactions in white matter pathology$580,492
R01 · FY2020 · DA
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injury$615,583
R01 · FY2019 · DA · contact PI
HIV opiate interactions in white matter pathology$580,492
R01 · FY2019 · DA
HIV opiate interactions in white matter pathology$529,386
R01 · FY2018 · DA
Glial Progenitors as Targets of HIV/Opiate Interactions$371,815
R01 · FY2018 · DA · contact PI
HIV opiate interactions in white matter pathology$529,386
R01 · FY2017 · DA
Glial origins of HIV and opiate-driven synaptodendritic injury$430,485
R01 · FY2017 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$373,187
R01 · FY2017 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$462,701
R01 · FY2016 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$369,455
R01 · FY2016 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$465,718
R01 · FY2015 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$367,588
R01 · FY2015 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$472,811
R01 · FY2014 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$379,908
R01 · FY2014 · DA · contact PI
Glial origins of HIV and opiate-driven synaptodendritic injury$443,305
R01 · FY2013 · DA · contact PI
Treatment for Dysmyelination in PMD and SPG2$181,217
R21 · FY2013 · NS · contact PI
Treatment for Dysmyelination in PMD and SPG2$237,613
R21 · FY2012 · NS · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$315,502
R01 · FY2011 · DA · contact PI
White matter changes in HIV models$183,138
R21 · FY2011 · NS · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$325,260
R01 · FY2010 · DA · contact PI
White matter changes in HIV models$224,250
R21 · FY2010 · NS · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$373,750
R01 · FY2009 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$328,545
R01 · FY2009 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$328,545
R01 · FY2008 · DA · contact PI
Glial Progenitors as Targets of HIV/Opiate Interactions$330,035
R01 · FY2007 · DA · contact PI
Opioids Modulate Oligodendrocyte Development & Function$251,718
R01 · FY2006 · DA · contact PI
Controlling Apoptosis in Oligondendrocytes$275,120
R01 · FY2005 · NS
Opioids Modulate Oligodendrocyte Development &Function$257,775
R01 · FY2005 · DA
Controlling Apoptosis in Oligondendrocytes$275,120
R01 · FY2004 · NS
Opioids Modulate Oligodendrocyte Development &Function$257,556
R01 · FY2004 · DA
Opioids Modulate Oligodendrocyte Development &Function$281,813
R01 · FY2003 · DA
Controlling Apoptosis in Oligondendrocytes$275,120
R01 · FY2003 · NS
Controlling Apoptosis in Oligondendrocytes$296,070
R01 · FY2002 · NS